"ranibizumab" meaning in English

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "",
        "3": "-zumab",
        "t2": "humanized monoclonal antibody"
      },
      "expansion": "[Term?] + -zumab (“humanized monoclonal antibody”)",
      "name": "af"
    }
  ],
  "etymology_text": "From [Term?] + -zumab (“humanized monoclonal antibody”).",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "ranibizumab (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms suffixed with -zumab",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "topical",
          "langcode": "en",
          "name": "Pharmaceutical drugs",
          "orig": "en:Pharmaceutical drugs",
          "parents": [
            "Drugs",
            "Matter",
            "Pharmacology",
            "Chemistry",
            "Nature",
            "Biochemistry",
            "Medicine",
            "Sciences",
            "All topics",
            "Biology",
            "Fundamental"
          ],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2007 January 27, Andrew Pollack, “Eye Drug Might Raise Risk of Stroke, Genentech Says”, in New York Times",
          "text": "Lucentis, also called ranibizumab, is approved to treat age-related macular degeneration, the leading cause of blindness in the elderly.",
          "type": "quotation"
        }
      ],
      "glosses": [
        "A monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab, used as an antiangiogenic."
      ],
      "id": "en-ranibizumab-en-noun-ljRHa56u",
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "monoclonal antibody",
          "monoclonal antibody"
        ],
        [
          "fragment",
          "fragment"
        ],
        [
          "murine",
          "murine"
        ],
        [
          "antibody",
          "antibody"
        ],
        [
          "bevacizumab",
          "bevacizumab"
        ],
        [
          "antiangiogenic",
          "antiangiogenic"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab, used as an antiangiogenic."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ],
      "wikipedia": [
        "ranibizumab"
      ]
    }
  ],
  "word": "ranibizumab"
}

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "",
        "3": "-zumab",
        "t2": "humanized monoclonal antibody"
      },
      "expansion": "[Term?] + -zumab (“humanized monoclonal antibody”)",
      "name": "af"
    }
  ],
  "etymology_text": "From [Term?] + -zumab (“humanized monoclonal antibody”).",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "ranibizumab (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English term requests",
        "English terms suffixed with -zumab",
        "English terms with quotations",
        "English uncountable nouns",
        "en:Pharmaceutical drugs"
      ],
      "examples": [
        {
          "ref": "2007 January 27, Andrew Pollack, “Eye Drug Might Raise Risk of Stroke, Genentech Says”, in New York Times",
          "text": "Lucentis, also called ranibizumab, is approved to treat age-related macular degeneration, the leading cause of blindness in the elderly.",
          "type": "quotation"
        }
      ],
      "glosses": [
        "A monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab, used as an antiangiogenic."
      ],
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "monoclonal antibody",
          "monoclonal antibody"
        ],
        [
          "fragment",
          "fragment"
        ],
        [
          "murine",
          "murine"
        ],
        [
          "antibody",
          "antibody"
        ],
        [
          "bevacizumab",
          "bevacizumab"
        ],
        [
          "antiangiogenic",
          "antiangiogenic"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab, used as an antiangiogenic."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ],
      "wikipedia": [
        "ranibizumab"
      ]
    }
  ],
  "word": "ranibizumab"
}